

Exhibit 2055
Materials Considered by Dr. Thomas A. Hope, M.D.

Exhibit No.	Description
1001	U.S. Patent No. 10,980,901 (“the ’901 patent”)
1002	Declaration of Dr. Rebecca Abergel, Ph.D.
1003	Curriculum Vitae of Dr. Rebecca Abergel, Ph.D.
1004	File History of U.S. Patent No. 10,980,901
1005	Marc A. Bjurlin, et al., Imaging and evaluation of patients with high-risk prostate cancer, 12 Nature Reviews Urology 617 (2015) (“Bjurlin”).
1006	Kristell Chatalic, et al., 213Bi-labeled PSMA-targeting agents for alpha radionuclide therapy of prostate cancer, 57 J. Nuclear Med. 137 (2016) (“Chatalic”).
1007	Emre Demirci, 68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma, 41 Eur. J. Nuclear Med. Molecular Imaging 1461 (2014) (“Demirci”).
1008	Catherine A. Foss, et al., Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer, 11 Clinical Cancer Rsch. 4022 (2005) (“Foss”).
1009	Shawn Hillier, et al., [131I] MIP-1375, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted therapy of prostate cancer (PCa), 52 J. Nuclear Med. 361 (2011) (“Hillier 2011”).
1010	Shawn Hillier, et al., [131I] MIP-1466, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for argeted radiotherapy of prostate cancer (PCa), 53 J. Nuclear Med. 170 (2012) (“Hillier 2012”).
1011	Joseph G. Jurcic, et. al., Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML), 128 Blood 4050 (2016) (“Jurcic”).
1012	Susan J. Mandel, et al., Superiority of Iodine-123 Compared with Iodine-131 Scanning for Thyroid Remnants in Patients with Differentiated Thyroid Cancer, 26 Clinical Nuclear Med. 6 (2001) (“Mandel”).
1013	Michael R. McDevitt, et al., Tumor Therapy with Targeted Atomic Nanogenerators, 294 Science 1537 (2001) (“McDevitt 2001”).
1014	Michael R. McDevitt, et al., Design and synthesis of 225Ac radioimmunopharmaceuticals, 57 Applied Radiation & Isotopes 841 (2002) (“McDevitt 2002”).
1015	Matthias Miederer, et al., Preclinical Evaluation of the α -Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors, 14 Clinical Cancer Rsch. 3555 (2008) (“Miederer 2008a”).
1016	Dianne E. Milenic & Martin W. Brechbiel, Targeting of Radio-Isotopes for Cancer Therapy, 3 Cancer Biology & Therapy 361 (2004) (“Milenic”).
1017	George Sgourous, et al., MIRD Pamphlet No. 22

	(Abridged): Radiobiology and Dosimetry of α -Particle Emitters for Targeted Radionuclide Therapy, 51 J. Nuclear Med. 311 (2010) (“MIRD Pamphlet”).
1018	Natsuko Normura, et al., Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases, 14 Cancer Cell Int’l 1 (2014) (“Nomura”).
1019	Martin G. Pomper, et al., 11C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase), 1 Molecular Imaging 96 (2002) (“Pomper”).
1020	Justin R. Hubenak, et al., Mechanisms of injury to normal tissue after radiotherapy: a review, 133 Plastic Reconstructive Surgery 49 (2014) (“Hubenak”).
1021	Jeffery S. Ross, et al., Correlation of Primary Tumor Prostate-Specific Membrane Antigen Expression with Disease Recurrence in Prostate Cancer, 9 Clinical Cancer Rsch. 6357 (2003) (“Ross”).
1022	David A. Scheinberg & Michael R. McDevitt, Actinium-225 in targeted alpha-particle therapeutic applications, 4 Current Radiopharmceuticals 306 (2011) (“Scheinberg”).
1023	David A. Silver, et al., Prostate-specific Membrane Antigen Expression in Normal and Malignant Human Tissues, 3 Clinical Cancer Rsch. 81 (1997) (“Silver”).
1024	Baris Turkbey, et al., Multiparametric Prostate Magnetic Resonance Imaging in the Evaluation of Prostate Cancer, 66 CA: Cancer J. for Clinicians 326 (2016) (“Turkbey”).
1025	U.S. Patent No. 10,471,160 (“the ’160 patent”).
1026	U.S. Patent No. 10,398,791 (“the ’791 patent”).
1027	Martina Weineisen, et al., Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer, 4 EJNMMI Rsch. 1 (2014) (“Weineisen 2014”).
1028	Martina Weineisen, et al., 68Ga-and 177Lu-labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies, 56 J. Nuclear Med. 1169 (2015) (“Weineisen 2015”).
1029	Alla G. Wernicke, et al., Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers, 122 APMIS 482 (2014) (“Wernicke”).
1030	Matthias Miederer, et al., Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications, 60 Advanced Drug Delivery Revs. 1371 (2008) (“Miederer 2008b”).
1031	Clemens Kratochwil, et al., Ac-225-DOTATOC - an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors, 56 J. Nuclear Med. 1232 (2015) (“Kratochwil”).
1032	Randall D. Knight, Physics For Scientists and Engineers 1369–70 (Adam Black et al. eds., vol. 5 2005) (“Knight”).
1033	Liang Zhao, et al., Clinical pharmacology considerations in biologics development, 33 Acta Pharamacologica Sinica 1339 (2012) (“Zhao”).
1034	U.S. Dep’t Health & Hum. Servs., Anthropometric Reference Data for Children and Adults: United States, 2015–2018 Series 3, 9 (2021) (“HHS”).

1035	Nerissa Viola-Villegas & Robert P. Doyle, The coordination chemistry of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (H4DOTA): Structural overview and analyses on structure–stability relationships, 253 Coordination Chemistry Reviews 1906 (2009) (“Viola-Villegas”).
1036	Nima Sharifi, et al., Androgen Deprivation Therapy for Prostate Cancer, 294 JAMA 238 (2005) (“Sharifi”).
1037	Nat’l Cancer Inst., SEER Cancer Stat Facts: Prostate Cancer, seer.cancer.gov, https://seer.cancer.gov/statfacts/html/prost.html (last visited Jan. 31, 2023) (“NCI”).
1038	Sharmila Banerjee, et al., Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications, 115 Chem. Revs. 2934 (2015) (“Banerjee”).
1039	Arundhati Ghosh & Warren D.W. Heston, Tumor Target Prostate Specific Membrane Antigen (PSMA) and its Regulation in Prostate Cancer, 91 J. Cellular Biochemistry 528 (2004) (“Ghosh”).
1040	Materials Considered by Dr. Abergel.
2001	National Institutes of Health Cancer Registration & Surveillance Modules Cancer Classification, https://training.seer.cancer.gov/disease/categories/classification.html (“NIH”)
2002	B. Zielinska, et al., “An Improved Method for the Production of Ac225/Bi-213 from Th-229 for Targeted Alpha Therapy”, Solvent Extraction and Ion Exchange, 2007;25(3):339-49 (“Zielinska”)
2003	Christos Apostolidis, et al., “Production of Ac-225 from Th-229 for targeted alpha therapy”, Analytical Chemistry, 2005;77(19):6288-91 (“Apostolidis”)
2004	Cytarabine Injection U.S. Food and Drug Administration Label, Hospira, Inc. (2020) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf (“Cytarabine FDA”)
2005	Thomas Langbein, et al., “Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine”, Journal of Nuclear Medicine, Sep. 2019, Vol. 60, No. 9 (Supplement 2) 13S-19S (“Langbein”)
2006	Rodrigo Bovolin de Medeiros, et al., “Metastatic castration-resistant prostate cancer (mCRPC) treated with 225Ac-PSMA-617. Case report”, Brazilian Journal Of Oncology (2019) (“de Medeiros”)
2007	de Kruijff, RM, et al., A Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters?, <i>Pharmaceuticals</i> 2015; 8, 321-336 (“de Kruijff”)
2008	DeBlonde, GJ, Abergel, RJ, “Active Actinium,” <i>Nat Chem.</i> , vol. 8, no. 11, pg. 1084 (November 2016) (“Abergel 2016”)
2009	Pallares RM and Abergel RJ, Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand? <i>Front. Med.</i> 2022; 9:1020188 (“Abergel 2022”)
2010	Declaration of Dr. Thomas A. Hope
2011	Transcript of Deposition of Rebecca Abergel, Ph.D., Fusion Pharmaceuticals, Inc. -v- Universität Heidelberg, et al. (PTAB), November 16, 2023 9 (“Abergel Tr.”)

2012	Tranel J, Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow, <i>Phys. Med. Biol.</i> 66 (2021) 035016 (“Tranel”)
2013	Vallabhajosula et al., “Prediction of Myelotoxicity Based on Bone Marrow Radiation-Absorbed Dose: Radioimmunotherapy Studies Using 90Y- and 177Lu-Labeled J591 Antibodies Specific for Prostate-Specific Membrane Antigen,” <i>J. Nucl. Med.</i> , vol, 46, no. 5, pgs. 850-858 (2005) (“Vallabhajosula”)
2014	Cloutier, et al, MIRD Pamphlet No. 21, Dose Estimate Report No. 2, “Summary of Current Radiation Dose Estimates to Humans from 66Ga-, 67Ga-, 68Ga-, and 72Ga-citrate,” <i>J. Nucl. Med.</i> , vol. 14, no. 10, pgs. 755-756 (1973) (“Cloutier”)
2015	Denison, TA, Tumor Heterogeneity and its Implication to Drug Delivery, <i>J. Control. Release</i> 2012, 164(2): 187-191 (“Denison”)
2016	Forrer, F, et al., Treatment with ¹⁷⁷ Lu-DOTATOC of Patients with Relapse of Neuroendocrine Tumors After treatment with ⁹⁰ Y-DOTATOC, <i>J Nucl Med.</i> 2005; 46:1310–1316 (“Forrer”)
2017	Morton, JJ, et al. Humanized mouse xenograft models: narrowing the tumor-microenvironment gap, <i>Cancer Res.</i> 2016; 76(21): 6153–6158 (“Morton”)
2018	Jaggi, SJ, et al. Efforts to Control the Errant Products of a Targeted In vivo Generator, <i>Cancer Res.</i> 2005; 65: (11) (“Jaggi”)
2019	Schwartz, J, et al., Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody, <i>Phys Med Biol.</i> 2011; 56(3): 721–733 (“Schwartz”)
2020	Dorso, L, et al., Long-Term Toxicity of 213Bi-Labelled BSA in Mice, <i>PLoS ONE</i> 2016; 11, e0151330 (“Dorso”)
2021	Miederer, M, et al., Pharmacokinetics, Dosimetry, and Toxicity of the Targetable Atomic Generator, 225Ac-HuM195, in Nonhuman Primates, <i>J Nucl. Med.</i> 2004; 45:129–137 (“Miederer 2004”)
2022	Kratochwil et al., “ ²²⁵ Ac-PSMA-617 for PSMA-Targeted α -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer,” <i>Journal of Nuclear Medicine</i> , vol. 57, no. 12, pgs. 1941-1944 (2016) (the “Kratochwil paper”)
2023	Common Terminology Criteria for Adverse Events (CTCAE), V. 5.0, November 27, 2017, U.S. Dept. Health & Human Services (“CTCAE”)
2024	Benesova, M, et al., Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer, <i>J Nucl Med</i> 2015; 56:914–920 (“Benesova”)
2025	https://jnm.snmjournals.org/content/57/12.cover-expansion
2026	Fanti, S, et al. Highlights of the 30th Annual Congress of the EANM, Vienna 2017: “Yes we can – make nuclear medicine great again,” <i>Eur. J. Nuc. Med. Mol. Im.</i> 2018; 45:1781–1794 (“Fanti”)
2027	https://www.eanm.org/congresses-events/awards-grants/winners/
2028	Alam, MR, et al., A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer, <i>Cureus</i> 2022; 14(9): e29369 (“Alam”)
2029	https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed_citedin&from_uid=27390158
2030	https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=225Ac-PSMA-617+for+PSMA-

	Targeted+ α -Radiation+Therapy+of+Metastatic+Castratio...
2031	https://www.altmetric.com/details/9534712/citations
2032	Afshar-Oromieh et al., "The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions," <i>J. Nucl. Med.</i> , vol. 56, no. 11, 1697-1705 (2015) ("Afshar-Oromieh")
2033	Tagawa ST, et al., "Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer," <i>Cancer</i> 2010, 116(4 Suppl):1075-83 ("Tagawa 2010")
2034	Tagawa ST, et al., "Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 in men with metastatic castration-resistant prostate cancer," <i>Front Oncol</i> 2013, 26:3:214 ("Tagawa 2013")
2035	Tagawa ST, et al., "Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of ^{225}Ac -J591," <i>J Clin Oncol</i> 2023, 3:JCO2300573 ("Tagawa 2023")
2036	Zalutsky et al., "Clinical experience with alpha-particle emitting ^{211}At : treatment of recurrent brain tumor patients with ^{211}At -labeled chimeric antitenascin monoclonal antibody 81C6," <i>J. Nucl. Med.</i> Vol. 49, no. 1, pgs. 30-38 (2008) ("Zalutsky")
2037	Abbas et al., "Experimental α -particle radioimmunotherapy of breast cancer using ^{227}Th -labeled p-benzyl-DOTA-trastuzumab," <i>EJNMMI Res.</i> Vol. 1, no. 1, pg.18 (2011) ("Abbas")
2038	Parker et al., "Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial," <i>Eur. Urol.</i> Vol. 70, no. 5, pgs. 875-883 (2016) ("Parker")
2039	Meredith et al., "Dose escalation and dosimetry of first-in-human α radioimmunotherapy with ^{212}Pb -TCMC-trastuzumab," <i>J. Nucl. Med.</i> , vol. 55, no. 10, pgs. 1636-1642 (2014) ("Meredith")
2040	Cordier et al., "Targeted alpha-radionuclide therapy of functionally critically located gliomas with ^{213}Bi -DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial," <i>Eur. J. Nucl. Med. Mol. Imaging</i> , vol. 37, no. 7, pgs. 1335-1344 (2010) ("Cordier")
2041	Müller et al., "A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α - and β - radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative," <i>J. Nucl. Med.</i> , vol. 53, no. 12, pgs. 1951-1959 (2012) ("Müller")
2042	Lin M, et al., Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives, <i>Cancer Biother Radiopharm</i> 2021 Apr;36(3):237-251 ("Lin")
2044	Kratochwil, C, et al., Targeted α -Therapy of Metastatic Castration-Resistant Prostate Cancer with ^{225}Ac -PSMA-617: Dosimetry Estimate and Empiric Dose Finding, <i>J Nucl Med</i> 2017; 58:1624–1631 ("Kratochwil 2017")

2045	Sathekge, M, et al., Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving ²²⁵ Ac-PSMA-617 Radioligand Therapy, <i>J Nucl Med</i> 2020; 61:62–69 (Sathekge 2020”)
2046	Pimm et al, “Blood and tissue kinetics of radiolabelled anti-CEA monoclonal antibody and F(ab)2 and Fab fragments in nude mice with human tumour xenografts: implications for tumour imaging and radioimmunotherapy,” <i>Nucl. Med. Commun.</i> , vol. 10, no. 8, pgs. 585-593 (1989) (“Pimm”)
2047	Burnett, AK, et al., A Comparison of Low-Dose Cytarabine and Hydroxyurea With or Without All-trans Retinoic Acid for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome in Patients Not Considered Fit for Intensive Treatment, <i>Cancer</i> 2007;109:1114–24 (“Burnett”)
2048	Winter, JN, et al., Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. <i>Cancer</i> 1985; 56(3):443-9 (“Winter”)
2049	Tilly, H, et al., Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients, <i>Cancer</i> 1985; 55(8):1633-6 EXHIBIT 2048 (“Tilly”)
2050	Cheson, BD, et al., A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes, <i>J Clin Oncol</i> 1986; 4(12):1857-64 (“Cheson”)
2051	Nonnekens, J., et al., ²¹³ Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-StrandBreaks in Prostate Cancer Xenografts, <i>Canc. Bioth. Rad.</i> 2017, 32 (2), 67-73 (“Nonnekens”)
2052	Sathekge, M., et al., ²²⁵ Ac-PSMA-617 in chemotherapy-naïve patients with advanced prostate cancer: a pilot study, <i>Eur J Nucl Med Mol Imaging</i> 2019, 46:129–138 (“Sathekge 2019”)
2053	Feuerecker, B., et al., Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution? <i>J Nucl Med</i> 2023; 64:685–692 (“Feuerecker”)
2054	Center MM, et al., International variation in prostate cancer incidence and mortality rates. <i>Eur Urol.</i> 2012;61(6):1079–92
2056	Curriculum Vitae of Dr. Thomas Hope, M.D.
2057	Cimons et al., “Cancer Drugs Face Long Road From Mice to Men,” <i>Los Angeles Times</i> , https://www.latimes.com/archives/la-xpm-1998-may-06-mn-46795-story.html (1998).